Abstract
The potential tumor suppressor protein prohibitin can prevent cell proliferation and this required its binding to the Rb protein. Prohibitin could repress the transcriptional activity of E2F family members and this required a part of the marked box region of E2F. The sub-cellular localization of prohibitin has been variously attributed to the mitochondria as well as the inner cell membrane. Here we show that a subset of prohibitin molecules are present in the nucleus where it co-localizes with the Rb protein. Deletion of a putative amino-terminal membrane-docking domain of prohibitin had no effect on its ability to suppress cell proliferation or inhibit E2F activity. Our experiments show that a 53 amino-acid stretch of E2F1 is sufficient for being targeted by prohibitin; fusion of this region to GAL4–VP16 construct could make it susceptible to prohibitin-mediated, but not Rb-mediated repression. Prohibitin, like Rb, could repress transcription from SV40 and major late promoters when recruited directly to DNA. Prohibitin mediated transcriptional repression required histone-deacetylase activity, but unlike Rb, additional co-repressors like N-CoR are also involved. Repression by prohibitin correlates with histone deacetylation on promoters and this was reversed by IgM stimulation of cells; IgM did not affect Rb-mediated repression or deacetylation of the promoters. Prohibitin thus appears to repress E2F-mediated transcription utilizing different molecular mediators and facilitate channeling of specific signaling pathways to the cell cycle machinery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams PD, Kaelin WJ . 1995 Semin. Cancer Biol. 6: 99–108
Adams PD, Kaelin WJ . 1996 Curr. Top. Microbiol. Immunol. 208: 79–93
Adnane J, Shao Z, Robbins PD . 1995 J. Biol. Chem. 270: 8837–8843
Alberts AS, Geneste O, Triesman R . 1998 Cell 92: 475–487
Amann JM, Nip J, Strom D, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW . 2001 Mol. Cell. Biol. 21: 6470–6483
Brehm A, Kouzarides T . 1999 Trends Biochem. Sci. 24: 142–145
Brehm A, Miska EA, McCance D, Reid JL, Bannister AJ, Kouzarides T . 1998 Nature 391: 597–601
Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch D, Hall PA, Wright EG . 2001 Exp. Cell Res. 265: 262–273
Collingwood TM, Urnov FD, Wolffe AP . 1999 J. Mol. Endocrinol. 23: 255–275
Dahiya A, Wong S, Gonzalo S, Gavin M, Dean DC . 2001 Mol. Cell 8: 557–569
Dedon PC, Soults JA, Allis CC, Gorovsky MA . 1991 Analytical. Biochem. 197: 83–90
Delage-Mourroux R, Martini PG, Choi I, Kraichely DM, Hoeksema J, Katzenellenbogen BS . 2000 J. Biol. Chem. 275: 35848–35856
Dyson N . 1998 Genes Dev. 12: 2245–2262
Fusaro G, Wang S, Chellappan SP . 2002 Oncogene 21: 4539–4548
Harbour JW, Dean DC . 2000a Curr. Opin. Cell. Biol. 12: 685–689
Harbour JW, Dean DC . 2000b Nat. Cell. Biol. 2: E65–E67
Howe L, Brown CE, Lechner T, Workman JL . 1999 Crit. Rev. Eukaryot. Gene Expr. 9: 231–243
Ikonen E, Fiedler K, Parton RG, Simons K . 1995 Febs Letts. 358: 273–277
Johnson DG, Schwarz JK, Cress WD, Nevins JR . 1993 Nature 365: 349–352
Johnson DG, Schneider-Broussard R . 1998 Front Biosci. 3: d447–d448
Luo RX, Dean DC . 1999 J. Natl. Cancer Inst. 91: 1288–1294
Luo RX, Postigo AA, Dean DC . 1998 Cell 92: 463–473
Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW . 1998 Mol. Cell. Biol. 18: 7176–7184
Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A . 1998 Nature 391: 601–605
Martinez-Balbas M, Bauer U-M, Nielsen SJ, Brehm A, Kouzarides T . 2000 EMBO J. 19: 662–671
McClung JK, Jupe ER, Liu X-T, Dell'Orco RT . 1995 Exper. Gerontol. 30: 99–124
Meloni AR, Smith EJ, Nevins JR . 1999 Proc. Natl. Acad. Sci. USA 96: 9574–9579
Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS . 1999 Proc. Natl. Acad. Sci. USA 96: 6947–6952
Muller H, Helin K . 2000 Biochim. Biophys. Acta 1470: M1–M12
Nevins JR . 1998 Cell Growth Differ. 9: 585–593
Nielsen SJ, Schneider R, Bauer IM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE, Kouzarides T . 2001 Nature 412: 561–565
Nijtmans LG, Artal SM, Grivell LA, Coates PJ . 2002 Cell Mol. Life Sci. 59: 143–155
Nijtmans LG, de Jong L, Artal Sanz M, Coates PJ, Berden JA, Back JW, Muijsers AO, van der Spek H, Grivell LA . 2000 EMBO J. 19: 2444–2451
Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP . 2000 Nat. Genet. 25: 338–342
Ross JF, Liu X, Dynlacht BD . 1999 Mol. Cell. 3: 195–205
Sambrook J, Fritsch E, Maniatis T . 1989 Molecular Cloning: Laboratory Manual 2nd edn Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press pp. 16.59–16.62
Steglich G, Neupert W, Langer T . 1999 Mol. Cell. Biol. 19: 3435–3442
Terashima M, Kim KM, Adachi T, Nielsen PJ, Reth M, Kohler G, Lamers MC . 1994 EMBO J. 13: 3782–3792
Thompson WE, Powell JM, Whittaker JA, Sridaran R, Thomas KH . 1999 Anat. Rec. 256: 40–48
Wang S, Nath N, Adlam M, Chellappan S . 1999a Oncogene 18: 3501–3510
Wang S, Nath N, Fusaro G, Chellappan S . 1999b Mol. Cell. Biol. 19: 7447–7460
Wang S, Ghosh R, Chellappan S . 1998 Mol. Cell. Biol. 18: 7487–7498
Weintraub SJ, Prater CA, Dean DC . 1992 Nature 358: 259–261
Xu L, Rosenfeld MG . 1999 Curr. Opin. Genet. Dev. 9: 140–147
Zhang Y, Chellappan SP . 1995 Oncogene 10: 2085–2093
Zhang SH, Gavin M, Dahiya A, Postigo AA, Ma S, Luo RX, Harbour JW, Dean DC . 2000 Cell 101: 79–89
Acknowledgements
We thank Scott Hiebert for helpful discussions and generous gift of reagents, and Joseph Nevins for different reporters and the GAL4-Rb construct. This work was supported by the grant CA 77301 from the NCI to SP Chellappan. G Fusaro is a recipient of a DOD student fellowship for breast cancer research (DAMD-17-01-1-0215).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, S., Fusaro, G., Padmanabhan, J. et al. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 21, 8388–8396 (2002). https://doi.org/10.1038/sj.onc.1205944
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205944
Keywords
This article is cited by
-
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo
Journal of Experimental & Clinical Cancer Research (2023)
-
Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis
Nature Communications (2022)
-
Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria
Cell Death & Disease (2020)
-
Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases
Cellular and Molecular Life Sciences (2020)
-
NAL8 encodes a prohibitin that contributes to leaf and spikelet development by regulating mitochondria and chloroplasts stability in rice
BMC Plant Biology (2019)